Evidence map›Paper›PMID 23152803›Full record

ArticlePloS one2012

HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies.

Paolo Monini, Aurelio Cafaro, Indresh K Srivastava, Sonia Moretti, Victoria A Sharma, Claudia Andreini, Chiara Chiozzini, Flavia Ferrantelli, Maria R Pavone Cossut, Antonella Tripiciano and 34 more

8 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 8 registered trials, which are not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00751595 phase2completednot on this map

A Phase II Randomized, Open Label, Immunogenicity and Safety Trial of the Vaccine Based on the Recombinant Biologically Active HIV-1 Tat Protein in Anti-Tat Negative HIV-1 Infected HAART-treated Adult Subjects.

TypeinterventionalSponsorBarbara Ensoli, MDRan2008 to 2012Enrolled168ConditionsHIV InfectionsArmsTat protein
NCT01024556 completednot on this map

Observational Study With Additional Diagnostic Procedures on Anti-Tat Immune Response in HIV-1-infected HAART-treated Adult Subjects

TypeobservationalSponsorBarbara Ensoli, MDRan2008 to 2012Enrolled142ConditionsHIV Infection
NCT01029548 completednot on this map

Observational Study With Additional Diagnostic Procedures on Anti-Tat Immune Response in HIV-1-infected Asymptomatic Adult Subjects

TypeobservationalSponsorBarbara Ensoli, MDRan2008 to 2012Enrolled73ConditionsHIV Infections
NCT01513135 phase2completednot on this map

A Phase Il, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers

TypeinterventionalSponsorBarbara Ensoli, MDRan2012 to 2014Enrolled200ConditionsHIV InfectionsArmsTat, Placebo
NCT02118168 completednot on this mapstarted 2013, after this paper: background citation

Observational study for the extended follow-up of the patients enrolled in the phase ii therapeutic clinical trial iss t-002

TypeobservationalSponsorBarbara Ensoli, MD, PhDRan2013 to 2016Enrolled93ConditionsHIV InfectionArmsNo intervention
NCT02712489 completednot on this mapstarted 2015, after this paper: background citation

A Roll-over Observational Study for the Extended Follow-up of the Volunteers of the ISS T-003 Trial (ISS T-003 EF-UP)

TypeobservationalSponsorBarbara Ensoli, MD, PhDRan2015 to 2016Enrolled179ConditionsHIV InfectionsArmsNo intervention
NCT04263207 suspendednot on this mapstarted 2020, after this paper: background citation

Observational Study for the Evaluation of the Role of HIV-1 Tat Protein and Anti-Tat Immune Response in Peripheral Blood HIV Reservoir Dynamics

TypeobservationalSponsorBarbara Ensoli, MD, PhDRan2020 to 2025Enrolled100ConditionsHIV/AIDSArmsNo intervention
NCT05680948 completednot on this mapstarted 2023, after this paper: background citation

A Roll-Over Observational Study for the Extended Follow-Up of the Volunteers of the ISS T-003 Trial (ISS T-003 EF-UP2020)

TypeobservationalSponsorIstituto Superiore di SanitàRan2023 to 2024Enrolled179ConditionsHIV Infections
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.Microbiology and molecular biology reviews : MMBR · 2016
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Anti-Tat immunity defines CD4EBioMedicine · 2021
    Article
  14. Review
  15. Article
  16. Review
  17. HIV-1 Tat: Role in Bystander Toxicity.Frontiers in cellular and infection microbiology · 2020
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

44 authors at 7 institutions in 2 countries.

Paolo MoniniNational AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Aurelio Cafaro
Indresh K Srivastava
Sonia Moretti
Victoria A Sharma
Claudia Andreini
Chiara Chiozzini
Flavia Ferrantelli
Maria R Pavone Cossut
Antonella Tripiciano
Filomena Nappi
Olimpia Longo
Stefania Bellino
Orietta Picconi
Emanuele Fanales-Belasio
Alessandra Borsetti
Elena Toschi
Ilaria Schiavoni
Ilaria Bacigalupo
Elaine Kan
Leonardo Sernicola
Maria T Maggiorella
Katy Montin
Marco Porcu
Patrizia Leone
Pasqualina Leone
Barbara Collacchi
Clelia Palladino
Barbara Ridolfi
Mario Falchi
Iole Macchia
Jeffrey B Ulmer
Stefano Buttò
Cecilia Sgadari
Mauro Magnani
Maurizio P M Federico
Fausto Titti
Lucia Banci
Franco Dallocchio
Rino Rappuoli
Fabrizio Ensoli
Susan W Barnett
Enrico Garaci
Barbara Ensoli
Istituto Superiore di Sanità · ITNovartis (United States) · USUniversity of Florence · ITSan Gallicano Hospital · ITUniversity of Ferrara · ITNovartis (Italy) · ITUniversity of Urbino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Use of Env in HIV vaccine development has been disappointing. Here we show that, in the presence of a biologically active Tat subunit vaccine, a trimeric Env protein prevents in monkeys virus spread from the portal of entry to regional lymph nodes. This appears to be due to specific interactions between Tat and Env spikes that form a novel virus entry complex favoring R5 or X4 virus entry and productive infection of dendritic cells (DCs) via an integrin-mediated pathway. These Tat effects do not require Tat-transactivation activity and are blocked by anti-integrin antibodies (Abs). Productive DC infection promoted by Tat is associated with a highly efficient virus transmission to T cells. In the Tat/Env complex the cysteine-rich region of Tat engages the Env V3 loop, whereas the Tat RGD sequence remains free and directs the virus to integrins present on DCs. V2 loop deletion, which unshields the CCR5 binding region of Env, increases Tat/Env complex stability. Of note, binding of Tat to Env abolishes neutralization of Env entry or infection of DCs by anti-HIV sera lacking anti-Tat Abs, which are seldom present in natural infection. This is reversed, and neutralization further enhanced, by HIV sera containing anti-Tat Abs such as those from asymptomatic or Tat-vaccinated patients, or by sera from the Tat/Env vaccinated monkeys. Thus, both anti-Tat and anti-Env Abs are required for efficient HIV neutralization. These data suggest that the Tat/Env interaction increases HIV acquisition and spreading, as a mechanism evolved by the virus to escape anti-Env neutralizing Abs. This may explain the low effectiveness of Env-based vaccines, which are also unlikely to elicit Abs against new Env epitopes exposed by the Tat/Env interaction. As Tat also binds Envs from different clades, new vaccine strategies should exploit the Tat/Env interaction for both preventative and therapeutic interventions.

Indexed as

AIDS VaccinesAnimalsAntibodies, NeutralizingBinding SitesDendritic Cellsenv Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHumansIntegrinsMacaca fascicularisMaleMolecular Docking SimulationNeutralization TestsAIDS VaccinesAntibodies, Neutralizingarginyl-glycyl-aspartic acidenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesHIV Envelope Protein gp120IntegrinsOligopeptidesReceptors, CCR5Receptors, CXCR4Recombinant Proteinstat Gene Products, Human Immunodeficiency VirusVaccines, Virus-Like Particle

Identifiers

PMID23152803
PMCPMC3496724
OpenAlexW2139235922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

and 2 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.